WeBD.Tokyo is launching cdmo.jp, a Japan-focused discovery platform that maps “technologies Japan doesn’t have” and “technologies only Japan has,” connecting pharmaceutical teams with the right CDMO partners. The site uses a structured taxonomy (dosage form, modality, scale, GMP scope, inspection history, equipment, analytics, references, videos) so Japanese sponsors and overseas CDMOs can find each other quickly and credibly.
Why this matters now
- Japan’s CDMO demand is rising across small molecules, injectables, and advanced modalities—but information remains fragmented across languages and websites.
- For European and North American CDMOs, the barrier is less about capability and more about discoverability, trust, and local context. cdmo.jp addresses exactly this gap with curated, comparable profiles and Japan-native distribution.
What is cdmo.jp?
cdmo.jp is a Japan-first discovery platform that organizes CDMO capabilities and makes them comparable for Japanese decision-makers. Each profile follows a shared taxonomy and machine-readable tags for fast filtering and matching by CMC, MSAT, QA, and BD teams in Japan.
- Company Directory & Profiles: structured filters (e.g., dosage form, modality, scale, EU/US/JP GMP scope, inspection history, equipment, analytics, case studies, videos)
- Japanese-language category pages: designed for search and shareability in Japan
- Service explainer pages: how the platform supports both sponsors and vendors
Who it’s for
- Overseas CDMOs & biotechs seeking qualified exposure, inbound requests, and long-term brand presence in Japan (beyond one-off trade shows)
- Japanese sponsors who want a shortlist of high-fit partners—especially for “no-overlap” capabilities that are scarce domestically
What clients get (WeBD.Tokyo subscribers)
- Pro-grade profile on cdmo.jp
Structured profile (taxonomy + tags) for high-intent search and filtering, plus editorial that maps your process to local expectations (GxP nuance, tech-transfer readiness, documentation culture). - Japan-native presence & PR distribution
Ongoing Japanese posts and updates, optimized for local channels to reach buyers who aren’t active on LinkedIn. - Warm intros & event leverage
Pre-screened intro requests, agenda building around BioJapan/Interphex, and “trust-first” follow-ups tailored to Japanese norms.
For Japanese sponsors
Quickly filter by what matters—for example: transdermal patches, lyophilized injectables, high-potency suites, solid-state R&D, aseptic fill-finish, or viral vectors. See process readiness (scale, inspection history) and evidence (analytics/tooling, case references) before outreach—saving cycles for your CMC and procurement teams.
Roadmap
- Q4 2025: expand directory coverage; deeper advanced-therapy filters (vector type, MOI ranges, cleanroom class, closed systems)
- Q1 2026: profile verification badges; optional data-room hooks for due-diligence readiness
Call for partners (Founding cohort)
We’re onboarding a limited cohort of European CDMOs/biotechs with “no-overlap” tech—teams confident they can solve problems Japanese sponsors cannot easily source domestically. If that’s you, let’s talk.
FAQ
How is cdmo.jp different from a simple vendor list?
Every profile uses a shared taxonomy and machine-readable tags, making capabilities comparable for Japanese decision-makers. It’s built for discovery and evaluation—not just listing.
Do you support PR and lead follow-ups in Japanese?
Yes. WeBD.Tokyo publishes & distributes Japanese content and runs “trust-first” follow-ups aligned with local norms, then routes qualified requests to you.
What if our capability is niche?
Perfect. cdmo.jp is optimized for “no-overlap” technologies—capabilities that are scarce in Japan and valuable to sponsors looking for real differentiation.